Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on September 8, 2016. The registrant is a California corporation focused on the development of diagnostic tests for lung cancer, bladder cancer, and breast cancer. The filing serves to disclose a presentation by the Chief Executive Officer at the Annual Gateway Conference.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate event rather than a financial statement.
Material Changes
No material financial changes or operational updates are reported in this filing. The document solely announces a scheduled presentation regarding the company's diagnostic test development pipeline.
Guidance, Outlook, and Risks
- Event Disclosure: CEO William Annett presented information on diagnostic test development at the Annual Gateway Conference on September 8, 2016, in San Francisco.
- Forward-Looking Statements: The filing includes standard disclaimers that statements regarding future plans, beliefs, and expectations are forward-looking and subject to risks detailed in the company's Form 10-K and 10-Q filings.
- Access: A live webcast and archived replay of the presentation were made available via the company's investor relations website.
Key Facts for Investor Verification
- Verify the content of the presentation slides (Exhibit 99.1) regarding the status of lung, bladder, and breast cancer diagnostic tests.
- Review the company's most recent Form 10-K and 10-Q for detailed risk factors and financial data not included in this 8-K.
- Confirm the company's current name and ticker status, as the metadata lists "Insight Molecular Diagnostics Inc." while the filing header identifies "OncoCyte Corporation."